Tonix Pharmaceuticals Holding Corp.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $TNXP in the last 30 days.
See all $TNXP insider activity →Tonix Pharmaceuticals (TNXP) received a Paragraph IV notice from Dr. Reddy’s for a generic version of TONMYA. Dr. Reddy’s challenged four patents in an ANDA filing, triggering a 45-day window for Tonix to sue. Tonix plans to enforce its IP but cannot predict litigation outcomes or generic entry timing.
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 1, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) received a notice (the “Notice”) from Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, “DRL”) stating that DRL filed an Abbreviated New Drug Application
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Other Events. Exhibit 99.01 Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA ® New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.) Commercial and government payer
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning TNXP (Tonix Pharmaceuticals Holding Corp.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent TNXP coverage spans regulation, corporate actions and insider activity.
The filing could lead to a generic entry, pressuring Tonix's share price.
The filing introduces legal risk and may delay generic competition, likely weighing on TNXP price.
Potential revenue uplift and improved market perception for Tonix.
Potential market upside if trial enrollment proceeds and data are positive; risk if delays or negative data.
Insider buying may signal confidence, but the purchase size is modest.
AlphAI scores every news story that mentions TNXP with an AI model for sentiment and relevance, and aggregates insider trades from Tonix Pharmaceuticals Holding Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tonix Pharmaceuticals (TNXP) received a Paragraph IV notice from Dr. Reddy’s for a generic version of TONMYA. Dr. Reddy’s challenged four patents in an ANDA filing, triggering a 45-day window for Tonix to sue. Tonix plans to enforce its IP but cannot predict litigation outcomes or generic entry timing.
1 min readTonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 1, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) received a notice (the “Notice”) from Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, “DRL”) stating that DRL filed an Abbreviated New Drug Application
1 min readTonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Other Events. Exhibit 99.01 Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA ® New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.) Commercial and government payer
2 min readTonix Pharmaceuticals (TNXP) is targeting growth for its fibromyalgia drug, TONMYA, by focusing on prescribers with a history of diagnosing the condition. The company plans to start a Phase II trial for its Lyme disease prevention candidate, TNX-4800, early next year. Tonix had $176 million in cash and no debt at the end of Q2, with a cash runway into Q2 2027.
2 min readLEDERMAN SETH (Chief Executive Officer) purchased 2,000 indirectly-held shares of Tonix Pharmaceuticals Holding Corp. (TNXP) at $13.79 on 2026-08-27.
1 min readTonix Pharmaceuticals' TNX-801, an investigational mpox vaccine, showed promise in preclinical studies, offering durable immunity and potential advantages over existing vaccines. According to Sina Bavari, PhD, the vaccine demonstrated robust immune responses and protection in animal models. Tonix aims to address unmet needs in infectious disease preparedness, with TNX-801 being part of its broader biodefense strategy. The company highlights the importance of next-generation vaccines in preventin
3 min readBAGGER RICHARD H purchased 1,000 shares of Tonix Pharmaceuticals Holding Corp. (TNXP) at $12.60 on 2026-08-20.
1 min readTonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Interim Chief Medical Officer On August 18, 2026, the Board of Directors of Tonix Pharmaceuticals Holding Corp. (the “Compa
3 min readTonix Pharmaceuticals (TNXP) reported Q2 2026 net product revenue of $13.5 million, including $11.0 million TONMYA net sales, up from $2.0 million a year earlier. TONMYA generated 12,592 prescriptions and expanded payer coverage to 136 million lives. Cash was $176.2 million at June 30, 2026. R&D rose to $19.4 million; net loss was $40.6 million.
6 min readTonix Pharmaceuticals Holding reported Q2 2026 revenue of about $13.544M, up from $1.998M a year earlier, largely driven by TONMYA sales (about $11M). The company posted a net loss of about $40.552M, and basic EPS loss narrowed to $2.44. The stock fell about 2% on the day.
6 min read
